What to do: Contact your pharmacy to confirm if you are taking medication from the affected lot. If you are, stop taking it and return it to your pharmacy for a replacement product and proper disposal.
Who this is for: General public
Affected products
Product
DIN
Lot
Expiry
Jamp-Atorvastatin 40 mg tablets
02391074
MHC1403A
2023-09-30
Issue
Jamp Pharma Corporation is recalling one lot (MHC1403A) of Jamp-Atorvastatin 40 mg tablets due to possible contamination with latex pieces during manufacturing. A piece of latex was found in one tablet from the affected lot.
Atorvastatin is a prescription drug used to treat high cholesterol and other fats (such as triglycerides) in the blood, and to prevent cardiovascular disease such as heart attacks.
Ingesting latex can pose serious health risks for people with latex allergies, including severe allergic reactions (anaphylaxis). Symptoms of anaphylaxis include breathing difficulties, nausea, vomiting, and low blood pressure. Anaphylaxis can be life threatening. In addition, foreign material in the tablets may change their shape, which could make them difficult to swallow and lead to choking.
The Department is monitoring the company's recall and will inform Canadians if any new health risks are identified.
What you should do
Contact your pharmacy to confirm if you are taking medication from the affected lot. If you are, stop taking it and return it to your pharmacy for a replacement product and proper disposal.
Contact Jamp Pharma Corporation by calling toll-free at 1-866-399-9091, extension 501, or by email at [email protected], if you have questions about this recall.
With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories...
NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have officially entered into a dynamic strategic partnership to collaboratively focus on the future of global health and wellness. Synergistically leveraging their collective expertise...
Drug Farm announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of DF-003, a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1) inhibitor for clinical evaluation in...
'Companion Diagnostics: Technologies and Markets' is all about using special tests alongside certain medicines to figure out which treatment will work best for each person. These tests are called companion diagnostics because they go together with...
WellSync, an API-driven virtual care service provider, today announced its partnership with The Vitamin Shoppe to launch Whole Health Rx, a cutting-edge telehealth service providing access to GLP-1 medications for weight management. WellSync provides...
May 17, 2024 Three studies demonstrate how Philips MCOT wearable ambulatory monitoring ECG and proprietary AI models applied to ECG digital biomarkers can help to improve diagnosis, reduce readmissions, and lower costs Amsterdam, the Netherlands...